Metabolic disorder

Innovent Announced Clinical Data of Multiple Trials Will be Presented at the 2022 ESMO-IO and ASH Annual Meetings

Retrieved on: 
Monday, November 28, 2022
Autoimmune disease, Autoimmunity, Metastasis, Environment, CML, Medicine, Nature, NSCLC, Selpercatinib, Metabolic disorder, Hospital, Chemistry, CMC, Soochow University, TKI, Eli Lilly and Company, Mutation, First Affiliated Hospital of Xinjiang Medical University, Eli Lilly, Trial of the century, Ophthalmology, Peking Union Medical College, Ramucirumab, HKEX, Control, News, Tolerability, NDA, Efficacy, Cancer, Social conditions in Honduras, Integrity, Stock exchange, Main, MD Anderson Cancer Center, Sintilimab, Bevacizumab, The First Affiliated Hospital of Wenzhou Medical University, NMPA, Motherboard, Vaccine, Management, Pharmaceutical industry, Patient, Safety, Spotlight Innovation, Hematology, Incyte

On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Key Points: 
  • On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.
  • Since its inception, Innovent has developed a fully integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • An additional 2 assets are under NMPA NDA review, 5 assets are in Phase 3 or pivotal clinical trials, and 20 more molecules are in clinical studies.
  • Innovent has built an international team with advanced talent in high-end biological drug development and commercialization, including many global experts.

Veterinary Telemedicine Company Dutch Launches Pet Insurance in Partnership with Pets Best

Retrieved on: 
Tuesday, November 22, 2022
Professional Services, Health, Consumer, Telemedicine, Virtual Medicine, Insurance, Pets, Veterinary, Dog, Cat, Parent, Allergy, Metabolic disorder, Anxiety, PETS, API, Flea, Telehealth, OTC, Partnership, Emergency, NYSE, Veterinarian, Insurance, Posterior cruciate ligament injury, Cancer, Policy, Safety, Accident, Travel, Pet, Health, Pet insurance, Patient, Degenerative disease, Veterinary medicine, Synchrony

Virtual veterinary care provider Dutch is partnering with Synchrony (NYSE: SYF), a consumer financial services company, to offer Pets Best insurance to its annual veterinary care members.

Key Points: 
  • Virtual veterinary care provider Dutch is partnering with Synchrony (NYSE: SYF), a consumer financial services company, to offer Pets Best insurance to its annual veterinary care members.
  • Pets Best is an ideal partner for Dutch, as they help us further our mission to provide seamless, transparent, quality veterinary care to pet parents across the country, he added.
  • Dutch and Pets Best are meeting the rising demand for veterinary services through API driven solutions, and innovative pet insurance products, further advancing the pet health industry.
  • Pet Insurance coverage offered and administered by Pets Best Insurance Services, LLC and underwritten by American Pet Insurance Company, a New York insurance company headquartered at 6100 4th Ave. S. Suite 200 Seattle, WA 98108.

Webinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious disease

Retrieved on: 
Thursday, November 10, 2022
People, PRS, Health, Prostate cancer, Guideline, Coronary artery disease, GTG, Risk, Genetypes, Colorectal cancer, Type 2 diabetes, DNA, Applied Genetic Technologies Corporation, NIPT, Risk assessment, Attitude, Metabolic disorder, Disease, ASX, Location, Metabolism, Ovarian cancer, Physician, Breast cancer, Patient, Vaccine, Research

A global leader in guideline driven genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands.

Key Points: 
  • A global leader in guideline driven genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands.
  • In addition to our patented GeneType polygenic based risk tests, our portfolio includes pharmacogenomics, Non-Invasive Prenatal Testing (NIPT), carrier screen testing, oncogenetic diseases, and pet care.
  • GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world.
  • Sporadic disease occurs in people with no family history of that disease and with no inherited change in their DNA making the risk difficult to predict with traditional methods.

ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®

Retrieved on: 
Thursday, November 3, 2022
Glucose, Private Securities Litigation Reform Act, Diet, Type 2 diabetes, Alloxan, Weight loss, SAN, CA, Obesity, PG, Risk, Industry, GLOBE, Vagotomy, SBIR, Ramakanta Panda, FDA, Safety, Metabolic disorder, Patient, Nasdaq, Plasma, Oxidative stress, Marketing, Roy Taylor (scientist), Research, Vagus nerve, Type 2, Anatomy, Collection, Annual report, U.S. Securities and Exchange Commission, Insulin, Stomach, Pancreas, Diabetes, Forward-looking statement, Reshaping Cultural Policies, CV, Liver, Technology, Security (finance), NIH, Hypoglycemia, SD, Insulin resistance, Ligation, Person, Miniature pig, Pharmaceutical industry, Medical device, T2DM

Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.

Key Points: 
  • Despite medication, surgery and diet, type 2 diabetes remains challenging to effectively treat, stated Jonathan Waataja, Director of Research at ReShape Lifesciences.
  • Previously, the area under the curve of oral glucose tolerance tests (OGTTs) was calculated to quantify glycemic control.
  • The opportunity to present such compelling data on our proprietary DBSN device at this industry conference is a testament to the market potential of the technology to treat type 2 diabetes, stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.
  • The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders.

Preclinical Data from iECURE’s GTP-506 Demonstrates Potential for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Wednesday, October 19, 2022
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, Gene expression, LinkedIn, Institute of Liver and Biliary Sciences, Time, Liver, Disease, Risk, Efficiency, Conference, Infant, Animal, Ammonia, Rose, ISH, Primate, Patient, Gene, Gene editing, Research, Pediatrics, International Conference on Availability, Reliability and Security, Coma, PCSK9, Technology, University, Nerve, Company, Mutation, Wilson, MD, Doctor of Philosophy, Mouse, AAV, Metabolic disorder, Blood, James Wilson, Biopsy, OTC, University of Pennsylvania, Ornithine transcarbamylase deficiency, Genome, GTP, Metabolism, PKU, Death, Chromosome, FDA, Human, Precision, Pharmaceutical industry, Vaccine, Medicine

iECUREs approach to gene editing for its initial programs, including OTC deficiency, relies on the delivery of twin adeno-associated virus (AAV)-based vectors carrying different payloads.

Key Points: 
  • iECUREs approach to gene editing for its initial programs, including OTC deficiency, relies on the delivery of twin adeno-associated virus (AAV)-based vectors carrying different payloads.
  • In the study presented by Lili Wang, PhD, of the University of Pennsylvanias GTP, potential efficacy of GTP-506 was demonstrated in an OTC-deficient mouse model.
  • Previously, data was presented showing efficient in vivo insertion in newborn NHPs as evidenced by biopsy three months post procedure.
  • 1 iECURE has licensed the ARCUS nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.

Decode Health Collaborates with Quest Diagnostics to Speed Biomarker Discovery for Drug and Diagnostics Development

Retrieved on: 
Tuesday, October 18, 2022
Quest Diagnostics, Decoding, Time, DGX, Therapy, Liver disease, MS, Non-alcoholic fatty liver disease, NAFLD, Multiple sclerosis, Machine learning, Organization, NYSE, Health, Patient, RNA, Research, Lists of diseases, Health equity, Quest, Senior, Precision medicine, Transcriptome, MD, Doctor of Philosophy, Metabolic disorder, CEO, Ecosystem, Medical device, Pharmaceutical industry

NASHVILLE, Tenn., Oct. 18, 2022 /PRNewswire/ -- Decode Health, a healthcare AI company that enables a partner ecosystem to innovate and solve data challenges involving disease risk, today announced a new phase of its collaboration with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, to empower drug and diagnostics research and development in the growing fields of metabolic disease and autoimmune neurology.

Key Points: 
  • Our work will create opportunities to fuel critical advances that unlock cutting-edge diagnostics and therapeutics.
  • [i]As part of the collaboration, Quest and Decode will share benefits from any research, data licensing, biomarker discovery or diagnostics development that emerge.
  • "Opportunities to significantly improve healthcare are hidden within data, especially for diagnostic and drug discoveries," said Chase Spurlock, PhD, Co-founder and CEO of Decode Health.
  • Decode Health is a healthcare AI company that powers an ecosystem of industry-leading diagnostic and pharmaceutical companies to unlock discoveries with data.

M6P Therapeutics Presents Novel AAV Gene Therapy Approach for the Treatment of Gaucher Disease at the ESGCT 29th Annual Congress

Retrieved on: 
Tuesday, October 11, 2022
Health, Other Science, General Health, Research, Science, Biotechnology, Congress, ESGCT, LSD, Therapy, Conference, Animal, Cell, Drug development, Gene, Publication, Glycogen storage disease, Tissue, Program, European Society of Gene and Cell Therapy, Technology, R, Gaucher's disease, Edinburgh International Conference Centre, Neuron, AAV, Phosphorylation, Metabolic disorder, Glycosphingolipid, CEO, A-DNA, CNS, Brain, Â, Mannose, GBA1, Central nervous system, M6P, Poster, Pharmaceutical industry, Fine chemical, Gaucher

The Congress takes place in-person and virtually in Edinburgh, Scotland from Oct. 11-14, 2022 at the Edinburgh International Conference Centre.

Key Points: 
  • The Congress takes place in-person and virtually in Edinburgh, Scotland from Oct. 11-14, 2022 at the Edinburgh International Conference Centre.
  • The data from this preclinical study illustrate the potential of our AAV-GBA-S1S3 gene therapy candidate for the treatment of Gaucher disease, including neuronopathic phenotypes, said Pawel Krysiak, President and CEO of M6P Therapeutics.
  • M012 is part of our pipeline of candidates leveraging a first-in-class co-expression S1S3 platform technology for the treatment of lysosomal storage disorders.
  • Gene therapy could be a potential therapeutic approach to treat all three types of Gaucher disease.

Bellevue Asset Management AG: Digital diabetes management – a success story for patients and for investors

Retrieved on: 
Thursday, October 6, 2022
Deloitte, G7, Glucose, Autoimmune disease, Smartphone, Investment, Medtronic, TEL, Judgement, Infarction, University, Kidney, Algorithm, Economics, CNMV, Meal, International Diabetes Federation, Tandem, Growth, Person, Lux, SICAV, Subcutaneous tissue, Obesity, Metabolic disorder, AG, Prospectus, Insulin, University of St. Gallen, FDA, Risk, Leadership, Diabetes, Time, FreeStyle, Insulin resistance, Research, Annual report, Severe cognitive impairment, Technology, House, SIX Swiss Exchange, Association, Life, AID, HSG, Dexcom, Patient, IDF, Blood, CHF, Post office box, Capital, CGM, Immune system, Stroke, G6, USD, Pancreas, Medical device, Pharmaceutical industry

According to the International Diabetes Federation (IDF), 530 million people worldwide, or one in ten adults, had diabetes in 2021.

Key Points: 
  • According to the International Diabetes Federation (IDF), 530 million people worldwide, or one in ten adults, had diabetes in 2021.
  • Compared to the diabetes statistics from the year 2000, the number of people with diabetes tripled over this period.
  • Thanks to new digital technologies, a diabetes patients time in range can be increased to 70-80% over a 24-hour period, depending on the patient.
  • Marcel Fritsch joined Bellevue Asset Management in 2008 and is Portfolio Manager of the Bellevue Medtech & Services Fund and the Bellevue Digital Health Fund.

Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer

Retrieved on: 
Thursday, September 29, 2022
GTG, ASX, Health, Journal, Woman, Risk, PRS, Risk assessment, Patient, Medicine, Breast cancer, Physician, Genetypes, Metabolism, Science, NASDAQ, Applied Genetic Technologies Corporation, GLOBE, Metabolic disorder, Precision medicine, Medical device, Medical imaging

The paper, titled Integrating Personalised Medicine into Preventative Care through Risk Stratification, outlines how GTGs geneType suite of risk assessment tools integrating common genomic markers of risk with traditional epidemiological risk factors, result in a net improvement in stratification over traditional risk assessments.

Key Points: 
  • The paper, titled Integrating Personalised Medicine into Preventative Care through Risk Stratification, outlines how GTGs geneType suite of risk assessment tools integrating common genomic markers of risk with traditional epidemiological risk factors, result in a net improvement in stratification over traditional risk assessments.
  • In a side-by-side comparison of clinical risk assessment models taken from data from the Nurses Health Study the geneType Risk Assessment Test for breast cancer showed a 9-fold improvement in identifying at-risk women when compared with traditional gold-standard (IBISv7), 22.4% of women compared to 2.5% over the actionable threshold respectively.
  • The publication includes three examples of discussions with patients and their clinicians where a clinician has the opportunity to use a risk score, such as geneType, to communicate a patients personal risk of developing disease.
  • The companys Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals.

ReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device

Retrieved on: 
Thursday, September 22, 2022
Diabetes, Health, Safety, Coma, Small Business Innovation Research, Blood, Metabolic disorder, Weight loss, FDA, Vagus nerve stimulation, Ramakanta Panda, PVN, Company, Miniature pig, Obesity, Stroke, Bluetooth, Pancreas, Patient, Reshaping Cultural Policies, Lists of diseases, Insulin, Technology, Type 2 diabetes, SBIR, Private sector, Nasdaq, Liver, CGM, Hypoglycemia, Collection, SAN, IPG, GLOBE, AI, NIH, Anatomy, Stomach, Pharmaceutical industry, Medical device

Specifically, the grant will fund development of the device for the treatment of hypoglycemia.

Key Points: 
  • Specifically, the grant will fund development of the device for the treatment of hypoglycemia.
  • The ReShape DBSN utilizes hypoglycemia vagal nerve stimulation (HVNS) using an implantable pulse generator (IPG) in a closed loop with a continuous glucose monitor (CGM).
  • The technology has demonstrated safety and efficacy through experiments in diabetic swine utilizing a previous Phase I funding from a NIH SBIR grant.
  • The award of our second NIH SBIR grant is a testament to the strength of the commercial opportunity of our novel DBSN device to address the significant, global diabetes market, stated Paul F. Hickey, President and Chief Executive Officer of ReShape Lifesciences.